相关实验视频
Updated: Sep 12, 2025

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
Published on: April 7, 2023
药物诱导骨质疏松症的性别差异:基于FAERS数据库的药监测研究
Lu Liu1, Yongjia Song1, Xiaoyu Liu1
1Clinical College of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
这项研究揭示了药物诱导骨质疏松症 (DIOP) 的显著性别特异性风险,确定了关键药物和发病模式. 这些发现对于加强患者安全和个性化药监策略至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 骨质疏松症研究研究
背景情况:
- 骨质疏松症是一个全球性的健康问题,而药物诱导骨质疏松症 (DIOP) 是一种新兴的不良药物效应.
- 了解DIOP的性别特异性风险和发病模式对于患者安全和有效的药物监督至关重要.
- 目前的知识差距阻碍了DIOP的有针对性的干预.
研究的目的:
- 调查药物诱导骨质疏松症 (DIOP) 的基于性别的差异.
- 识别与DIOP相关的药物并分析它们的发病模式.
- 用独立的不良事件数据库验证发现.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据的分析 (2004年第一季度至2024年第四季度).
- 药物的标准化 (RxNorm) 和不良事件 (MedDRA).
- 不成比例分析 (ROR,MGPS,BCPNN) 和通过加拿大警ADR数据库进行外部验证.
主要成果:
- 确定了236,928个与骨质疏松症有关的报告,其中女性占64.6%.
- 检测到68种与DIOP相关的药物,包括15种男性特异性和26种女性特异性风险药物.
- 通过外部验证证了32种具有潜在骨质疏松症风险的药物;注意到各种发病模式 (例如,upadacitinib,tenofovir).
结论:
- 在DIOP风险中存在显著的性别特异性差异,需要量身定制的药物监督.
- 研究结果支持针对骨质疏松症易患人群的个性化药物安全方法.
- 通过了解DIOP的性别特异性风险,可以改善知情的药物决策.
更多相关视频
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
相关概念视频
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Factors Affecting Drug Response: Overview
Factors Influencing Drug Absorption: Anatomical Parameters